A pooled analysis of two early-stage trials found that amsokigene autoleucel was manufactured successfully, was well tolerated and showed a preliminary efficacy signal in patients with immune checkpoint inhibitor-refractory melanoma.
Engineered tumor-infiltrating cell therapy shows early signal in melanoma resistant to checkpoint inhibitors
A pooled analysis of two early-stage trials found that amsokigene autoleucel was manufactured successfully, was well tolerated and showed a preliminary efficacy signal in patients with immune checkpoint inhibitor-refractory melanoma.
Frontiers in Oncology · CC BY 3.0 · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.